Related Experiment Video
Updated: Aug 11, 2025

Anesthesia and Intubation of Preadolescent Mouse Pups for Cardiothoracic Surgery
Published on: June 2, 2022
A new view on old problems in paediatric anaesthesia: premedication, postoperative agitation and dosing
1Paediatric Anaesthesia, Luzerner Kantonsspital, Luzern Switzerland.
Insights
Recent advances in pediatric anesthesia highlight the distinct roles of midazolam and dexmedetomidine for sedation and anxiety. New data also refines propofol dosing for pediatric patients.
Area of Science:
- Pediatric Anesthesia
- Pharmacology
- Sedation and Anxiolysis
Background:
- Recent developments in pediatric anesthesia have shown an undulating progression.
- Pharmacological premedication strategies are being reevaluated for efficacy and safety.
Approach:
- This review examines the defined anxiolytic and sedative properties of midazolam and alpha-2 agonists.
- It also assesses total intravenous anesthesia with propofol and alternative approaches for preventing emergence agitation.
- The theoretical basis for propofol dosing has been updated, challenging previous assumptions about its context-sensitive half-life.
Key Points:
- Midazolam is an effective anxiolytic, while dexmedetomidine offers superior sedation, particularly in the postoperative period and for diagnostic imaging.
- While total intravenous propofol is common for emergence agitation, co-medication with dexmedetomidine or opioids are viable alternatives.
- A multimodal approach to anesthesia is often advisable in clinical practice.
Conclusions:
- Midazolam and dexmedetomidine are not interchangeable; each has unique benefits.
- Midazolam remains a valuable anxiolytic, whereas dexmedetomidine excels in sedation and postoperative care.
- Emerging data will enable more precise, age-adapted propofol dosing in pediatric patients.
Purpose Of Review:
The aim of this review is to discuss recent developments in paediatric anaesthesia, which have evolved in an undulating fashion.
Recent Findings:
The role and efficacy of pharmacological premedication is reevaluated. The anxiolytic and sedative properties of midazolam and α 2 -agonists have now been defined more precisely. Both classes of drugs have their unique profile, and there is no reason to condemn one or the other. Midazolam is an excellent anxiolytic, whereas dexmedetomidine is superior in the postoperative period and for sedation during diagnostic imaging.A total intravenous technique with propofol is often considered to be the standard for the prevention of emergence agitation; but alternatives do exist, such as a co-medication with dexmedetomidine or opioids. In clinical reality, a multimodal approach may often be advisable.The theoretical basis for propofol dosing has recently been adapted. In contrast to previous beliefs, the context-sensitive half-life of propofol seems to be quite short beyond the first year of life.
Summary:
Midazolam and dexmedetomidine are not interchangeable; each compound has its pros and cons. As an anxiolytic drug, midazolam indisputably deserves its place, whereas dexmedetomidine is a better sedative and particularly beneficial in the postoperative period. New data will allow more precise age-adapted dosing of propofol.
Related Concept Videos
Parenteral Anesthetics: Overview
General Anesthesia: Overview
General anesthesia induces unconsciousness in the whole body, while the others target specific areas or sensations. It is administered to minimize adverse effects, maintain...
Factors Affecting Drug Response: Overview
Stages of General Anesthesia
Inhalational Anesthetics: Overview
Drug Delivery: Enteral Route

